Mesavin 1200 SR Tablet contains Mesalazine 1200 mg as its active ingredient, a well-established anti-inflammatory agent primarily used in the management of inflammatory bowel diseases such as ulcerative colitis and Crohn’s disease. Mesalazine acts locally on the colonic mucosa to inhibit the production of pro-inflammatory mediators including prostaglandins and leukotrienes, thereby reducing inflammation and promoting mucosal healing. The sustained-release formulation ensures gradual release of the drug throughout the gastrointestinal tract, enhancing therapeutic efficacy while minimizing systemic absorption and associated side effects. Mesavin 1200 SR is indicated for the induction and maintenance of remission in patients with mild to moderate ulcerative colitis and for the treatment of active distal colitis. It is generally well-tolerated, with common adverse effects including headache, abdominal pain, nausea, and diarrhea. Caution is advised in patients with hypersensitivity to salicylates or mesalazine, and renal function should be monitored periodically due to rare reports of nephrotoxicity. Mesavin 1200 SR should be administered as directed by a healthcare professional, with dosage adjustments based on clinical response and tolerability. This medication plays a crucial role in improving patient quality of life by controlling symptoms and preventing disease relapse.